The Science Advances publication details Cellgorithm™, a CRISPR-based technology that gives researchers greater control over gene activity and sets the stage for future applications in stem cell ...

Researchers from MIT, Northeastern University, and Meta recently released a paper suggesting that large language models (LLMs) similar to those that power ChatGPT may sometimes prioritize sentence ...

Local news about the companies, people and issues that impact business in Ottawa and beyond delivered to your email inbox. A local strategic communications firm is expanding to western Canada with a ...

In a recent study published in Communications Psychology, researchers from NYU led by Associate Professor of Biomedical Engineering at NYU Tandon and Neurology at NYU Grossman School of Medicine Adeen ...

GRAND RAPIDS, Mich. — If you ask Syntaxx about his origins, he'll tell you. "I am a computer program created by a team of developers," he says. If you ask him about the station with the most local ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. A Chicago biotechnology startup with roots at the ...

A few months ago, I had a discussion with some friends online. The premise of the discussion was that even if you account for complexity, shorter code is more likely to be bug-free code. As a C ...

MONTRÉAL, Oct. 3, 2023 /CNW/ -- Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, today announced its plans to acquire ...

Cell therapies are already here, with treatments now available for some cancers and rare diseases. But bringing such living medicines to more patients presents both scientific and financial challenges ...